Non-invasive Ocular Surface Measurements Before and After Interventions

This study is currently recruiting participants.
Verified May 2012 by University of Rochester
Sponsor:
Information provided by (Responsible Party):
University of Rochester
ClinicalTrials.gov Identifier:
NCT01228929
First received: October 25, 2010
Last updated: May 3, 2012
Last verified: May 2012
  Purpose

Objectively evaluate the ocular surface (pre-corneal tear film) of individuals prior to and after an intervention (such as a dry eye treatment, environmental change, artificial tear use, or contact lens wear) in a controlled-environmental chamber, over time using non-contact instruments.


Condition Intervention
Normal Subjects, Subjects Who Experience Dry Eye Symptoms, Subjects at Risk for Developing Dry Eye and Experienced Contact Lens Wearers.
Other: Patient-directed or physician-recommended interventions.
Other: Environmental Chamber
Drug: Eye Drop Intervention
Other: Contact Lens Intervention

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Non-invasive Ocular Surface Measurements Before and After Interventions

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Evaluation of Ocular Surface [ Time Frame: Over the course of one year ] [ Designated as safety issue: No ]
    Objectively evaluate the ocular surface (pre-corneal tear film) of individuals prior to and after an intervention (such as a dry eye treatment, environmental change, artificial tear use, or contact lens wear) in a controlled-environmental chamber, over time using non-contact instruments.


Estimated Enrollment: 200
Study Start Date: July 2010
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Patient-directed or physician-recommended interventions.
    These interventions may include obtaining baseline data (prior to the intervention) and after the intervention that may be performed at one or more visits. The subject's physician may recommend performing a dry eye treatment, such as wearing moisture retaining goggles, performing lid massage, using compresses or scrubs, or taking a nutritional supplement. The subject may decide to begin a homeopathic intervention such as water misting, humidifier use or exposure to an herbal scent. The subject may perform the intervention for a period of time and then come to the research site for measurements or may perform the intervention at the study site so measurements are timed close to the intervention. The study duration is one or two visits in one day each lasting about one hour. Depending on the intervention a second visit may be requested on the same day, for example, to determine if the effects of lid massage are effective for 6-8 hours.
    Other: Environmental Chamber
    Environmental chamber condition change interventions. Most studies will set the environmental conditions (temperature, humidity, airflow) to mimic typical office and home environments (68 to 72 degrees F and 20 to 50%). For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study we will have the subject acclimate to a set of environmental conditions (approximately 20 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit.
    Drug: Eye Drop Intervention
    This type of intervention will require a screening exam to confirm the subject's eye condition and suitability for study. These studies use FDA-approved over-the-counter eye drops, artificial tears or saline (dilute solution of salt water) used as indicated by the FDA. Dispensing will use a new single use container or separate bottle for each subject. We will instill one drop in the eye. The study length is one visit lasting a maximum of two hours.
    Other: Contact Lens Intervention
    This type of intervention will require a screening exam to confirm the subject's eye condition and suitability for study. We will have experienced lens wearers wear their own lenses or wear the same type of lenses (soft or rigid gas permeable [RGP]) within the FDA approved modality (daily, continuous or extended wear) and replacement cycle (for example, daily, one week, one month, etc.) as described in the lens package insert and/or prescribed by their eye care provider. We will take measurements of the subject without the lenses, have the subject insert the lenses, wait about five minutes for the eye to settle down, then take another set of measurements. The subject will then leave the site and return for a second visit at 6-8 hours of wear for an additional measurement and a final measurement five minutes after removal of the contact lenses. Each visit may take a maximum of one hour. If the subject did not wear his/her own pair of contact lenses, the subject will return the lenses.
  Eligibility

Ages Eligible for Study:   18 Years to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Individuals with dry eye diagnoses (aqueous deficient dry eye [ADDE], and/or evaporative dry eye), dry eye symptoms (as associated with Sjogren's Syndrome diagnosis), refractive surgery, contact lens use, and exposure to dry work environments are appropriate to correlate clinical tests, subjective responses and objective measurements of current ocular surface status and to study clinically-recommended or patient-directed dry eye treatments such as taking dietary supplements, wearing moisture-retaining goggles, performing lid massage, or using over the counter eye drops or artificial tears.
  • Individuals who do not currently have dry eye symptoms but who may be at risk for dry eye diagnosis, and those who have dry eye symptoms but no clinical dry eye diagnosis, are of interest to correlate clinical tests, subjective responses and objective measurements of current ocular surface status and, if symptoms appear or worsen, to correlate the data with the effect of environmental condition changes, such as increasing the humidity or reducing air flow, on the ocular surface
  • Experienced contact lens wearers are appropriate for studies that use their own lenses (soft, rigid gas permeable [RGP], hard [PMMA]) or the same type of lens within the FDA approved modality (daily, continuous or extended wear) and replacement cycle (for example, daily, one week, one month, etc.) as described in the lens package insert and/or prescribed by their eye care provider to investigate ocular surface data before, during and after lens use.
  • Normal individuals, those without a dry eye diagnosis, without dry eye symptoms or those who do not wear contacts to act as controls for the focus areas in the studies.

Exclusion Criteria:

Individuals with eye or medical condition(s) that contraindicate performing screening or measurements will not be eligible for this study. Specific examples include:

  • Individuals will not be dilated if an exam and/or medical history indicted they have a narrow anterior chamber angle, glaucoma, or other contraindications to dilation (like arterio-sclerotic cerebrovascular disease).
  • Individuals with the following will not participate in contact lens studies: presence of ocular or systemic allergies or disease (infection), clinically significant (grade 3 or 4) corneal edema, corneal vascularization, or any other abnormalities of the cornea, tarsal abnormalities or bulbar injection or use of medication that might interfere with contact lens wear.
  • Individuals will not participate in any aspect of the study if: they are pregnant or become pregnant or are lactating, have an infectious disease (e.g. hepatitis, tuberculosis) or have an immuno-suppressive disease (e.g. HIV).
  • Individuals with known sensitivity to dyes or to numbing drops will not be screened using these agents.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01228929

Contacts
Contact: Research Coordinator 585-273-4870 jeanette_zavislan@urmc.rochester.edu

Locations
United States, New York
Flaum Eye Institute at the University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Research Coordinator     585-273-4870        
Principal Investigator: James V Aquavella, MD            
Sub-Investigator: Geunyoung Yoon, Ph.D.            
Sub-Investigator: James M Zavislan, Ph.D.            
Sponsors and Collaborators
University of Rochester
  More Information

No publications provided

Responsible Party: University of Rochester
ClinicalTrials.gov Identifier: NCT01228929     History of Changes
Other Study ID Numbers: UR 32315
Study First Received: October 25, 2010
Last Updated: May 3, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Rochester:
Dry Eye
Non-invasive instruments
MGD
Eye Drops
Environment
Contact Lenses
OCT
Wavefront
Thermal Imaging

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Tetrahydrozoline
Nasal Decongestants
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Respiratory System Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 13, 2013